Early Access — free while we kick the tires
EdgarHawk

David Scott Moore

Director

Director

Latest: Director buying · June 2026

1 filing analyzed · 1 company · Latest 2026-06-15
Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗

Companies

Company Buys Sells Direction
Corvus Pharmaceuticals, Inc. CRVS 1 0 Net buying

Activity

June 2026
high
Buy
21,700 shares
$250,236
Significance 6/10

Director David Scott Moore buys 21,700 shares of CRVS at $11.53; stock down 55.8% from 52-week high amid ongoing losses.

Director David Scott Moore purchased 21,700 shares at $11.53 on 2026-06-11, establishing a non-derivative position of 21,700 shares while retaining 15,000 shares in stock options (Table II derivative holdings). The buy occurs in a depressed context: the stock trades 55.8% below its 52-week high of $26.95, down 23.0% over the prior 90 days, and the company posted a net loss of $-13.7M in its most recent full fiscal year. The purchase represents a material commitment ($250.2K) by a director into a company experiencing significant revenue headwinds and unprofitability, suggesting directional conviction at current valuation levels. With derivative holdings intact, this represents a selective accumulation of non-derivative equity rather than a blanket portfolio bet, and the 90-day decline provides the context for this entry timing.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access